These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 30036146)

  • 41. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
    Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D
    Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
    Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
    Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Xu M; Casio M; Range DE; Sosa JA; Counter CM
    Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
    Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
    [No Abstract]   [Full Text] [Related]  

  • 49. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
    Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
    Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
    Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Papillary thyroid cancer organoids harboring BRAF
    Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y
    J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    Chhabra G; Ahmad N
    J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.
    Bokharaie H; Kolch W; Krstic A
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
    Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
    Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
    van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
    Xing J; Liu R; Xing M; Trink B
    Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.